Eighty patients with advanced breast cancer were characterized by estrogen receptor (ER) status and by urine androgen (A) metabolites. After ovariectomy, patients with positive hormonal parameters were treated with hormonal therapy and patients with negative parameters were treated with chemotherapy. The results of the follow-up confirm that the survival is higher in patients with positive hormonal parameters (ER +, A+). In this group, the patients with increased urine androgen excretion (i.e. A+) apparently had a better long-term survival than ER + cases.
Get full access to this article
View all access options for this article.
References
1.
BlockG.E., JensenE.V., PollegT.Z.: The prediction of hormonal dependency of mammary cancer.Ann. Surg., 182: 342–346, 1975.
2.
De SombreE.R., SmithS., FergusonD.J., JensenE.V.: Prediction of breast cancer response to endocrine therapy.Cancer Chemother. Rep., 58: 513–517, 1974.
3.
GrattarolaR.: Ovariectomy alone or in combination with dexamethasone in patients with advanced breast cancer and high levels of testosterone secretion.J. Natl. Cancer Inst., 56: 11–15, 1976.
4.
GrattarolaR.: Considerazioni endocrinologiche sul carcinoma mammario. In: I Tumori della Mammella.VeronesiU., PerussiaA., EmanuelliH., and De LenaM. (Eds.), Casa Editrice Ambrosiana, Milano, 1977, pp. 35–42.
5.
LeungB.S., FletcherW.S., LindellT.D., WoodD.C., KrippaehnoW.W.: Predictability of response to endocrine ablation in advanced breast cancer.Arch. Surg., 106: 515–519, 1973.
6.
LiK., FooT., AdamsJ.B.: Products of dehydro-epiandrosterone metabolism by human mammary tumors and their influence on estrogen receptor binding.Steroids, 31: 113–127, 1977.
7.
LiK., AdamsJ.B.: Aromatization of testosterone and estrogen receptor levels in human breast cancer.J. Steroid Biochem., 14: 269–272, 1980.
8.
MastersJ.R.W., HowkinsR.A., SangsterK., HowkinsW., SmithI.I., ShivasA.A., RobertsM.M., ForrestA.P.M.: Estrogen receptors, cellularity, elastosis and menstrual status in human breast cancer.Eur. J. Cancer, 14: 303–307, 1978.
9.
McGuireW.L.: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy.Semin. Oncol., 5: 428–433, 1978.
10.
McIndoeJ.H.: Estradiol formation from testosterone by continuously cultured human breast cancer cells.J. Clin. Endocrinol. Metab., 49: 272–277, 1979.
11.
OrianaS., SecretoG., SeveriniA., Di FronzoG., Di GiuseppeM., ValagussaP., PredaF.: Bilateral ovariectomy in premenopausal patients with advanced breast cancer, after the evaluation of estrogen receptors and urinary androgen excretion.Breast Cancer Res. Treat., 2: 101–104, 1982.
12.
PereiE., WilkingD., KillingerD.W.: The conversion of androstanedione to estrone, estradiol and testosterone in breast tissue.J. Steroid Biochem., 13: 89–94, 1980.
13.
PetoR., PikeM.C., ArmitageP.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient.II: Analysis and examples. Br. J. Cancer, 35: 1–39, 1977.
14.
PredaF., OrianaS., Di FronzoG., SecretoG., SeveriniA., ScavoneG.F., CastagnolaG.: Long-term response to ovariectomy in 35 premenopausal patients with advanced breast cancer treated in coherence with hormonal tests.Tumori, 69: 343–347, 1983.
15.
SecretoG., FariselliG., BandieramonteG., RecchioneC., DatiV., Di PietroS.: Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast.Eur. J. Cancer Clin. Oncol., 19: 5–10, 1983.
